Considering the role of FLT3 in the pathogenesis of ALL and AML and the fact that identifying the beneficiaries of FLT3 inhibitors remains an enigma, we conducted a comprehensive analysis of pediatric ALL and AML cases. This evidence concerns the gene FLT3 and acute myeloid leukemia.